Arcus Biosciences Shareholders: Ownership Structure, Brands, and Acquisition History
Last updated: Sep-2026Ownership Structure
Stakes approximate based on latest filings.
Ownership Analysis
The ownership arrangement is itself the most important thing to understand about Arcus, because Gilead is far more than a 13 percent shareholder. Through a broad collaboration struck in 2020 and expanded with an additional 320-million-dollar investment in 2024, Gilead supplies upfront capital, reimburses research, holds options on programs, and lends the validation of a major partner, while gaining extensive rights over several of Arcus's most important candidates. Beyond Gilead, specialist biotech funds like Biotechnology Value Fund and index holders own the widely distributed remainder. For public shareholders, this creates a double-edged reality: the Gilead relationship funds a cash-burning enterprise and validates its science, but it also means the economics of key drugs are shared, and the company is dependent on collaboration funding to sustain development. What owners are backing is therefore not a self-sustaining business but a clinical pipeline partly financed and partly claimed by a larger partner, an arrangement common in biotech that trades some upside and independence for capital and credibility, and that leaves shareholders exposed to both clinical risk and the terms of a relationship they do not control.
Direct Owners
Institutional Shareholders
Shareholder Analysis
Almost none of Arcus's roughly 247 million dollars of revenue comes from selling medicine, because it has none approved; the figure reflects Gilead collaboration funding, and the company consumes cash advancing investigational drugs. The equity is thus a wager on clinical outcomes. Its promise lies in a pipeline led by casdatifan, an HIF-2 alpha inhibitor targeting kidney cancer in a validated mechanistic class, supported by immuno-oncology candidates and immunology programs, and in the Gilead partnership that funds the work and lends scientific credibility. The countervailing risks are severe and characteristic of clinical-stage biotech: most drug candidates fail, and 2025 already brought the discontinuation of upper-gastrointestinal studies of one program; the company burns cash and depends on collaboration funding and capital markets; Gilead controls extensive rights to key assets; and success would still require competing against entrenched oncology giants. This is not an investment to be weighed on earnings but on the probability and magnitude of clinical success, a binary, high-risk proposition in which casdatifan's data and the durability of the Gilead relationship matter far more than any current financial metric.
Brands, Subsidiaries & Companies Owned
| Name | Type | Description |
|---|---|---|
| Casdatifan | Brand | Investigational HIF-2 alpha inhibitor |
| Quemliclustat | Brand | Investigational CD73 inhibitor |
| Domvanalimab | Brand | Investigational TIGIT antibody |
| Zimberelimab | Brand | Investigational PD-1 antibody |
| Etrumadenant | Brand | Investigational adenosine receptor antagonist |
| Arcus Biosciences | Company | Clinical development and research platform |
Portfolio Analysis
Arcus has no marketed products and therefore no brands in any commercial sense; its identity resides entirely in a pipeline of investigational molecules and the science behind them. The lead candidate, casdatifan, is an HIF-2 alpha inhibitor aimed at kidney cancer, a mechanism validated by the success of others in the same class, and it is flanked by immuno-oncology programs including the TIGIT antibody domvanalimab, the PD-1 antibody zimberelimab, the CD73 inhibitor quemliclustat, and the adenosine-pathway antagonist etrumadenant, several developed within the Gilead collaboration. The strategy is to build differentiated combinations and next-generation agents in immuno-oncology and, increasingly, inflammation, leaning on a research platform designed to generate novel candidates. What stands in for competitive strength here is the quality of the science and the pipeline: the credibility of casdatifan's mechanism, the breadth of the immuno-oncology programs, and the validation implied by Gilead's partnership. But these are potential assets, not realized ones, and their worth depends entirely on clinical data, making the company's scientific promise something only successful trials can convert into genuine, durable value.
Market Share & Competitors
Bubble size reflects relative market share.
| Company | Market Share | Revenue | Key Strength |
|---|---|---|---|
| Arcus Biosciences ★ | N/A | $247M FY2025 | Clinical-stage oncology and immunology developer |
| Merck | N/A | $65B FY2025 | Global oncology leader with Keytruda |
| Bristol Myers Squibb | N/A | $48B FY2025 | Global immuno-oncology and cardiovascular company |
| Exelixis | N/A | $2.3B FY2025 | Kidney and liver cancer drug company |
| Akeso | N/A | $0.4B FY2025 | Antibody drug developer with immuno-oncology programs |
Competitive Analysis
Competition in oncology is brutal, and Arcus enters it as a small clinical-stage developer arrayed against the industry's giants. Its potential rivals include Merck, whose Keytruda dominates immuno-oncology, Bristol Myers Squibb, a leader in the field, the kidney-cancer specialist Exelixis whose franchise casdatifan would directly challenge, and emerging antibody developers such as Akeso. Against such competitors Arcus has no marketed products, limited resources, and a pipeline that must still prove itself, so its only credible path is scientific differentiation: casdatifan must show compelling data in kidney cancer, and its immuno-oncology combinations must offer something the incumbents lack. The Gilead partnership lends resources and validation that most small biotechs cannot match, a genuine competitive help. But the hazards dominate: entrenched competitors with approved drugs and vast budgets, the high failure rate of clinical development, dependence on collaboration funding, and the reality that even successful drugs must displace established standards of care. Arcus competes, in effect, on the promise of better science, and whether that promise translates into a defensible position depends entirely on clinical data that remains, for now, unproven against formidable and well-resourced rivals.
Acquisitions
Bubble size reflects relative deal value.
| Company Acquired | Deal Value | Year | Description |
|---|---|---|---|
| None | N/A | 2025 | Growth has centered on internally discovered programs and collaboration funding |
Acquisitions Analysis
Arcus has completed no meaningful acquisitions, and that absence is telling: its growth has come from internally discovered programs and, decisively, from collaboration rather than dealmaking. The structurally defining event in its history is not a purchase but the Gilead partnership, first struck in 2020 and expanded in 2024, which supplied upfront capital, research reimbursement, program options, and strategic validation in exchange for extensive rights over important candidates. That relationship has functioned as Arcus's principal source of external capital and credibility, substituting for the acquisitions or large capital raises that a cash-burning biotech would otherwise require. For shareholders, the implication is that value is created, or destroyed, in the laboratory and the clinic, not through M&A: the company advances its own molecules with collaboration funding, and its worth rises or falls on trial results. Future value therefore hinges on clinical execution and the terms of the Gilead relationship rather than on acquisitions, and the more relevant risk is not integration but the possibility that key programs fail or that the collaboration's economics leave public shareholders with a diminished share of any eventual success.
Acquisition Timeline
Merger & Spin-off History
Merger & Spin-off Analysis
There has been no merger or spinoff in Arcus's history; its corporate shape has been defined instead by a collaboration. Founded in 2015 and taken public in 2018, the company has remained an independent clinical-stage developer, and the single most consequential structural event was the 2020 Gilead partnership, later expanded in 2024. That arrangement, rather than any transaction, shaped the enterprise: it supplied capital, reimbursed research, granted Gilead options and rights over key programs, and made the larger company both a shareholder and a strategic partner deeply woven into Arcus's development plans. The effect is a structure in which Arcus remains nominally independent yet economically dependent on collaboration funding and strategically entangled with a much larger partner that holds extensive rights to its most important assets. For a cash-burning biotech, this is a common and rational structure, trading independence and some economics for capital and validation, but it leaves the company's fate tied to both clinical outcomes and the terms of a partnership it does not control, a defining feature of its corporate character rather than any merger or spinoff.
Ownership History
Ownership History Analysis
Arcus began in 2015 when Terry Rosen and colleagues set out to build a company on novel immuno-oncology science, and its decade since has been a clinical-stage journey punctuated by one defining relationship. An initial public offering in 2018 provided early capital, but the pivotal moment came in 2020, when Gilead entered a broad research-and-development partnership that supplied funding, validation, and options over key programs, expanding its investment further in 2024. The pipeline advanced unevenly, as biotech pipelines do: the company sharpened its focus in 2025 by discontinuing certain upper-gastrointestinal studies and concentrating on casdatifan in kidney cancer and its immunology programs. Through it all, Arcus has remained a pre-commercial business, its roughly 247 million dollars of revenue drawn from collaboration rather than sales. The history is that of a science-driven biotech that traded a share of its upside for the capital and credibility of a major partner, and whose ultimate worth still awaits the verdict of clinical trials, a company whose story remains unwritten because its lead medicines have yet to prove themselves.
Ownership Explained
Arcus Biosciences is a clinical-stage biopharmaceutical company in Hayward, California, developing cancer and inflammation therapies, and trading on the NYSE as RCUS. Its ownership carries a distinctive feature: Gilead Sciences holds roughly 13 percent as a strategic collaborator, with the remaining 87 percent public and specialist biotech investors such as Biotechnology Value Fund prominent among them. Founded in 2015 and employing about 670 people, the company reports roughly 247 million dollars of revenue, almost all of it collaboration funding rather than product sales, since its medicines remain investigational. Its pipeline centers on the HIF-2 alpha inhibitor casdatifan and several immuno-oncology candidates. This is a pre-commercial business whose value rests on clinical outcomes.
Owning Arcus is owning a portfolio of clinical bets, not a profitable enterprise, and the ownership structure underscores the point. Gilead's roughly 13 percent stake and its collaboration supply capital, research reimbursement, and strategic validation, but also hand a single partner extensive rights over important programs, so shareholders share the upside of key drugs with Gilead. The 247 million dollars of reported revenue is collaboration money, not commercial sales; the company burns cash developing medicines that may or may not succeed. What public holders are really backing is the probability-weighted value of a drug pipeline, above all casdatifan in kidney cancer, and the company's dependence on both clinical success and continued Gilead funding makes this a high-risk, binary-outcome equity rather than an operating business.